Development and Evaluation of a Novel Point-of-Use Quality Assurance Tool for Digital Pathology.


Journal

Archives of pathology & laboratory medicine
ISSN: 1543-2165
Titre abrégé: Arch Pathol Lab Med
Pays: United States
ID NLM: 7607091

Informations de publication

Date de publication:
10 2019
Historique:
pubmed: 26 4 2019
medline: 21 4 2020
entrez: 26 4 2019
Statut: ppublish

Résumé

Flexible working at diverse or remote sites is a major advantage when reporting using digital pathology, but currently there is no method to validate the clinical diagnostic setting within digital microscopy. To develop a preliminary Point-of-Use Quality Assurance (POUQA) tool designed specifically to validate the diagnostic setting for digital microscopy. We based the POUQA tool on the red, green, and blue (RGB) values of hematoxylin-eosin. The tool used 144 hematoxylin-eosin-colored, 5×5-cm patches with a superimposed random letter with subtly lighter RGB values from the background color, with differing levels of difficulty. We performed an initial evaluation across 3 phases within 2 pathology departments: 1 in the United Kingdom and 1 in Sweden. In total, 53 experiments were conducted across all phases resulting in 7632 test images viewed in all. Results indicated that the display, the user's visual system, and the environment each independently impacted performance. Performance was improved with reduction in natural light and through use of medical-grade displays. The use of a POUQA tool for digital microscopy is essential to afford flexible working while ensuring patient safety. The color-contrast test provides a standardized method of comparing diagnostic settings for digital microscopy. With further planned development, the color-contrast test may be used to create a "Verified Login" for diagnostic setting validation.

Identifiants

pubmed: 31021658
doi: 10.5858/arpa.2018-0210-OA
doi:

Substances chimiques

Coloring Agents 0
Eosine Yellowish-(YS) TDQ283MPCW
Hematoxylin YKM8PY2Z55

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1246-1255

Auteurs

Emily L Clarke (EL)

From the Section of Pathology and Tumour Biology, University of Leeds, Leeds, United Kingdom (Dr Clarke, Mr Sykes, Mr Wright, and Dr Treanor); Histopathology Department (Drs Clarke and Treanor) and Medical Physics Department (Dr Brettle), Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom; and the Division of Neurobiology, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Department of Clinical Pathology, Centre for Diagnostics, Region Östergötland, Sweden (Drs Boden and Treanor).

David Brettle (D)

From the Section of Pathology and Tumour Biology, University of Leeds, Leeds, United Kingdom (Dr Clarke, Mr Sykes, Mr Wright, and Dr Treanor); Histopathology Department (Drs Clarke and Treanor) and Medical Physics Department (Dr Brettle), Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom; and the Division of Neurobiology, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Department of Clinical Pathology, Centre for Diagnostics, Region Östergötland, Sweden (Drs Boden and Treanor).

Alexander Sykes (A)

From the Section of Pathology and Tumour Biology, University of Leeds, Leeds, United Kingdom (Dr Clarke, Mr Sykes, Mr Wright, and Dr Treanor); Histopathology Department (Drs Clarke and Treanor) and Medical Physics Department (Dr Brettle), Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom; and the Division of Neurobiology, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Department of Clinical Pathology, Centre for Diagnostics, Region Östergötland, Sweden (Drs Boden and Treanor).

Alexander Wright (A)

From the Section of Pathology and Tumour Biology, University of Leeds, Leeds, United Kingdom (Dr Clarke, Mr Sykes, Mr Wright, and Dr Treanor); Histopathology Department (Drs Clarke and Treanor) and Medical Physics Department (Dr Brettle), Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom; and the Division of Neurobiology, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Department of Clinical Pathology, Centre for Diagnostics, Region Östergötland, Sweden (Drs Boden and Treanor).

Anna Boden (A)

From the Section of Pathology and Tumour Biology, University of Leeds, Leeds, United Kingdom (Dr Clarke, Mr Sykes, Mr Wright, and Dr Treanor); Histopathology Department (Drs Clarke and Treanor) and Medical Physics Department (Dr Brettle), Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom; and the Division of Neurobiology, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Department of Clinical Pathology, Centre for Diagnostics, Region Östergötland, Sweden (Drs Boden and Treanor).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH